With the FDA approval of brensocatib, the first approved treatment specifically for non-cystic fibrosis bronchiectasis, what does this breakthrough mean for patients and clinicians? In this episode of the ATS Breathe Easy podcast, host Ugo Ezema, MD, Tulane, speaks with ATS Treasurer Gregory Tino, MD, ATSF, University of Pennsylvania, about the science behind brensocatib, findings from the ASPEN clinical trial, and promising new therapies on the horizon.